← Back to Search

LHRH Antagonist

Degarelix for Prostate Cancer

Phase 2
Waitlist Available
Led By Kim N Chi, MD
Research Sponsored by British Columbia Cancer Agency
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 8 weekly
Awards & highlights

Study Summary

Men with castrate resistant prostate cancer who are switched from a luteinizing hormone-releasing hormone (LHRH) antagonists from a LHRH agonist will experience a fall in prostate-specific antigen (PSA).

Eligible Conditions
  • Prostate Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~8 weekly
This trial's timeline: 3 weeks for screening, Varies for treatment, and 8 weekly for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
50% fall in PSA
Secondary outcome measures
Follicle stimulating hormone (FSH)
Luteinizing hormone (LH)
Testosterone (TT)
+4 more

Side effects data

From 2009 Phase 2 & 3 trial • 57 Patients • NCT00117286
40%
Hot flush
27%
Fatigue
23%
Injection site pain
23%
Injection site nodule
17%
Nausea
17%
Nasopharyngitis
17%
Prostatic specific antigen increased
17%
Upper respiratory tract infection
17%
Rash
13%
Hypertension
13%
Dyspnoea
13%
Cough
13%
Weight increased
13%
Anaemia
13%
Dizziness
10%
Pneumonia
10%
Vomiting
10%
Injection site erythema
10%
Insomnia
10%
Urinary tract infection
10%
Arthralgia
10%
Haemoglobin decreased
10%
Decreased appetite
10%
Hyperkalaemia
10%
Anxiety
10%
Pollakiuria
7%
Micturition urgency
7%
Chills
7%
Abdominal pain
7%
Constipation
7%
Gastrooesophageal reflux disease
7%
Inguinal hernia
7%
Oedema peripheral
7%
Hyperhidrosis
7%
Bundle branch block left
7%
Cataract
7%
Bronchitis
7%
Tooth abscess
7%
Influenza
7%
Contusion
7%
Procedural pain
7%
Fall
7%
Tooth fracture
7%
Gamma-glutamyltransferase increased
7%
Blood creatinine increased
7%
Renal failure
7%
Pruritus genital
7%
Nasal congestion
7%
Weight decreased
7%
Hyperlipidaemia
7%
Diabetes mellitus
7%
Urinary incontinence
7%
Gynaecomastia
7%
Benign prostatic hyperplasia
7%
Hiatus hernia
7%
Atrioventricular block first degree
7%
Myocardial infarction
7%
Injection site haematoma
7%
Pain
7%
Musculoskeletal pain
7%
Basal cell carcinoma
7%
Headache
7%
Epistaxis
7%
Pleural effusion
7%
Actinic keratosis
3%
Diverticulum
3%
Subarachnoid haemorrhage
3%
Colonic polyp
3%
Appendiceal abscess
3%
Dysuria
3%
Sarcoma
3%
Appendicitis perforated
3%
Injection site induration
3%
Metastasis to central nervous system
3%
Transient ischaemic attack
3%
Gastroenteritis viral
3%
Respiratory tract infection
3%
Pelvic fracture
3%
Muscular weakness
3%
Back pain
3%
Haematuria
3%
Erectile dysfunction
3%
Cardiac failure congestive
3%
Carotid artery occlusion
3%
Chronic obstructive pulmonary disease
3%
Deep vein thrombosis
3%
Injection site mass
3%
Injection site reaction
3%
Pyrexia
3%
Arthritis
100%
80%
60%
40%
20%
0%
Study treatment Arm
Degarelix (60 mg to 160 mg)
Degarelix (80 mg to 160 mg)

Trial Design

1Treatment groups
Experimental Treatment
Group I: DegarelixExperimental Treatment1 Intervention
Degarelix 240mg subcutaneously loading dose, then 80mg sc every month until disease progression.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Degarelix
FDA approved

Find a Location

Who is running the clinical trial?

Ferring PharmaceuticalsIndustry Sponsor
313 Previous Clinical Trials
440,818 Total Patients Enrolled
52 Trials studying Prostate Cancer
17,867 Patients Enrolled for Prostate Cancer
British Columbia Cancer AgencyLead Sponsor
171 Previous Clinical Trials
90,471 Total Patients Enrolled
24 Trials studying Prostate Cancer
5,812 Patients Enrolled for Prostate Cancer
Kim N Chi, MDPrincipal InvestigatorBritish Columbia Cancer Agency, Univeristy of British Columbia
5 Previous Clinical Trials
535 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Efficacy Study of Switching to a Lutenizing Hormone-releasing Hormone (LHRH) Antagonist From a LHRH Agonist to Treat Progressive Castrate Resistant Prostate Cancer (CRPC)
Kim Chi 2012. "Efficacy Study of Switching to a Lutenizing Hormone-releasing Hormone (LHRH) Antagonist From a LHRH Agonist to Treat Progressive Castrate Resistant Prostate Cancer (CRPC)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01630967.
All > Acth
~3 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top